Effects of nine antihypertensive drugs on blood pressure variability in sinoaortic-denervated rats

Acta Pharmacologica Sinica

Volumn 27, Issue 8, 2006, Pages 1013-1017

  Wang, Jin ^a,b   Shen, Fu Ming ^a   Wang, Min Wei ^b   Su, Ding Feng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antihypertensive drugs; Blood pressure; Blood pressure variability; Sinoaortic denervation

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CAPTOPRIL; CLONIDINE; HYDROCHLOROTHIAZIDE; NIFEDIPINE; NITRENDIPINE; PRAZOSIN; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CONTROLLED STUDY; DRUG EFFECT; HEART; MALE; NONHUMAN; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CAROTID SINUS; CLONIDINE; DENERVATION; HEART RATE; HYPERTENSION; MALE; NIFEDIPINE; PRESSORECEPTORS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHOLYTICS;

EID: 33746393309     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00381.x     Document Type: Article

References (21)

1. Jordan J, Tank J, Shannon JR, Diedrich A, Lipp A, Schroeder C, et al. Baroreflex buffering and susceptibility to vasoactive drugs. Circulation 2002; 105: 1459-64.
2. Norman RA Jr, Coleman TG, Dent AC. Continuous monitoring of arterial pressure indicates sinoaortic denervated rats are not hypertensive. Hypertension 1981; 3: 119-25.
3. Buchholtz RA, Nathan NA. Chronic lability of the arterial pressure produced by electrolytic lesions of the nucleus tractus solitarii in the rat. Circ Res 1984; 54: 227-38.
4. Su DF, Miao CY. Blood pressure variability and organ damage. Clin Exp Pharmacol Physiol 2001; 28: 709-15.
5. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5: 93-8.
6. Mancia G, Frattola A, Parati G, Santucciu C, Ulian L. Blood pressure variability and organ damage. J Cardiovasc Pharmacol 1994; 24: S6-11.
7. Miao CY, Su DF. The importance of blood pressure variability in rat aortic and left ventricular hypertrophy produced by sinoaortic denervation. J Hypertens 2002; 20: 1865-72.
8. Su DF, Miao CY. Reduction of blood pressure variability: a new strategy for the treatment of hypertension. Trends Pharmacol Sci 2005; 26: 388-90.
9. Miao CY, Xie HH, Zhan LS, Su DF. Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats. J Hypertens 2006; 24: 1137-46.
10. Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens 2003; 21: 1961-7.
11. Xie HH, Shen FM, Cao YB, Li HL, Su DF. Effect of low-dose ketanserin on blood pressure variability, baroreflex sensitivity and end-organ damage in spontaneously hypertensive rats. Clin Sci 2005; 108: 547-52.
12. 2 Gabor R, Marta M, Mark K, Emil M, Laszlo D. Experimental orthostasis elicits sustained hypertension, which can be prevented by sympathetic blockade in the rats. J Cardiovasc Pharmacol 2005; 45: 354-61.
13. Fu YJ, Shu H, Miao CY, Wang MW, Su DF. Restoration of baroreflex function by ketanserin is not blood pressure dependent in conscious freely moving rats. J Hypertens 2004; 22: 1165-72.
14. Xie HH, Miao CY, Jiang YY, Su DF. Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive rats. J Hypertens 2005; 23: 193-201.
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-71.
16. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
17. William C. Are there benefits to specific antihypertensive drug therapy? AM J Hypertens 2003; 16: 315-55.
18. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, et al. The felodipine event reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157-72.
19. Juline C. Pharmacological attenuation of blood pressure variability. Acta Pharmacol Sin 2005; 26: 1288-9.
20. Burattini R, Borgdorff P, Westerhof N. The baroreflex is counteracted by autoregulation, thereby preventing circulatory instability. Exp Physiol 2004; 89: 397-405.
21. Kornet L, Hoeks APG, Janssen BJA, Houben AJ, De Leeuw PW, Reneman RS. Neural activity of the cardiac baroreflex decreases with age in normotensive and hypertensive subjects. J Hypertens 2005; 23: 815-23.